End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
755,000 KRW | +0.53% | -4.43% | -0.66% |
05-23 | US FDA Approves Samsung Bioepis' Eye Disease Drug Opuviz | MT |
05-06 | Samsung Group Firms Set to Invest in US-based Latus Bio | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.66% | 39.15B | |
-2.09% | 90.02B | |
-15.83% | 31.71B | |
+62.42% | 26.47B | |
-21.68% | 14.34B | |
-8.73% | 12.89B | |
-10.32% | 11.18B | |
-45.77% | 10.97B | |
+3.45% | 8.94B | |
+92.69% | 7.51B |
- Stock Market
- Equities
- A207940 Stock
- News Samsung Biologics Co.,Ltd.
- Samsung Bioepis Granted Approval to Market Autoimmune Treatment in Europe